MedTrace Logo

LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia

NCT04385667 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2023-01-03

No results posted yet for this study

Summary

This randomized controlled trial is aimed to compare the efficacy between Megestrol acetate (MA) and the levonorgestrel intrauterine system (LNG-IUD) regarding the ability and duration to produce complete regression for cases with atypical endometrial hyperplasia.

Conditions

  • Atypical Endometrial Hyperplasia

Interventions

DEVICE

levonorgestrel intrauterine system (LNG-IUD)

progestin delivery for regression of atypical endometrial hyperplasia

DRUG

Oral Megesterol 160 mg daily

progestin delivery for regression of atypical endometrial hyperplasia

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Amr Alnemr, M.D. · Faculty of Medicine- Zagazig university

  • Hytham Atia, M.D. · Faculty of Medicine- Zagazig university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-20
Primary Completion
2022-12-01
Completion
2022-12-25

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04385667 on ClinicalTrials.gov